Compare iShares China Large-Cap ETF (FXI) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs GeneDx Holdings Corp — how do they compare? iShares China Large-Cap ETF trades at $34.25 (market cap $3.86B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: iShares China Large-Cap ETF is the larger of the two by market cap, and GeneDx Holdings Corp is more actively traded (734,640 versus 16,323,837). Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 150 Days and GeneDx Holdings Corp for 19 Days on average.
| FXI | WGS | |
|---|---|---|
Market Cap | $3.86B | $2.02B |
Volume | 16,323,837 | 734,640 |
52-Week High | $41.08 | $167.51 |
52-Week Low | $31.59 | $34.51 |
Typical Hold Time | 150 Days | 19 Days |
Sector | — | Health |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI trades at $33.45 with minimal daily movement (+0.09%), reflecting subdued momentum amid bearish technical signals. The ETF faces significant technical headwinds with 17 sell signals versus 1 buy, though oscillators remain neutral. Recent news highlights China's mixed economic signals, including strong export growth but persistent overcapacity concerns. The Trump-Xi summit in September 2026 offered limited progress on trade tensions, maintaining geopolitical uncertainty for Chinese equities.
FXI presents a value opportunity with a P/E ratio of 11.10—half the S&P 500's valuation—and a 1.98% yield, but faces substantial risks from China's economic rebalancing, weak domestic consumption, and potential export controls. Investor sentiment is cautious due to political and macroeconomic headwinds, though some analysts see long-term potential if China stabilizes growth.
GeneDx (WGS) trades at $67.73, down 1.17% today, showing mixed signals with bearish technical indicators but strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating expectations, and returned to adjusted profitability early. However, 2026 fundamentals show concerning trends with a net loss of $106 million and negative profit margins. Recent news highlights product innovations and leadership recognition, while technical analysis indicates the stock is trading near key support at $66.
The investment outlook presents a dichotomy between strong analyst conviction (90.9% buy ratings, $81 consensus target) and challenging fundamentals. While operational improvements and genomic testing growth offer potential upside, persistent losses and negative cash flow trends create significant execution risk. The stock's current position near support levels combined with oversold RSI readings suggests potential for near-term bounce, but sustainable gains require meaningful profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
